Industry Symposia
Symposia Information
The Unbearable Itch; Unveiling the Complexities of Prurigo Nodularis
Chronic prurigo, or prurigo nodularis (PN), is one of dermatology’s most challenging conditions, characterized by persistent itch and nodular lesions that severely impact patients’ lives. This session explores PN’s medical history, epidemiology and pathophysiology, including changes in skin architecture, key signaling molecules such as IL-31, and receptor complexes driving chronic itch. It also addresses the profound sensory, mental, and social burdens of PN, including its disruption of sleep and quality of life. Finally, treatment options will be reviewed, providing insights to enhance patient care by integrating the latest research with clinical expertise.
Speakers:
MD, PhD, Chief Physician, Associate Professor
Jesper Elberling
Managing Atopic Dermatitis: New Treatments & Clinical Insights - an interactive session on clinical cases
Moderator introduces the overall topic 10 minutes.
Each panelist introduces a topic 5 min. and then discuss a clinical case 8 min.
Round off 11 min.
Each panelist presents a case with data included followed by an interactive case discussion where cases are presented bit by bit, interrupted by a) interactive polls in the audience, visual on a central screen b) panel discussions of the possible/suggested solutions to specific challenges. Topics of the cases could e.g. be: 1) Body weight & Skin of color (SE), 2) head and neck, conjunctivitis, 3) immediate onset of action/long-term control.
Speakers:
Speaker and moderator: Stephan Weidinger
Speaker: Christian Vestergaard
Speaker: Jose Hernán Alfonso
Speaker: TBC
Research in Reality: RWE in Long Term AD and PN management
Join us for an insightful exploration of real world evidence from comprehensive registries on Atopic Dermatitis (AD) and Prurigo Nodularis (PN). This symposium will provide valuable insights into long-term treatment outcomes and their practical applications in clinical decisionmaking.
Distinguished panel:
- Johanna Mandelin, MD, PhD, Specialist in Dermatology and Allergology
- Simon Francis Thomsen, MD, PhD, Professor, Specialist in Dermatology
- Lian van der Gang, MD, senior PhD student and investigator of the Dutch BioDay registry.
- Kim Endre, MD, PhD, Specialist in Dermatology
- Laura Huilaja, MD, PhD, Adjunct professor, Specialist in Dermatology and Allergology
This symposium offers a unique opportunity to enhance your clinical approach with evidence-based insights from extensive patient data across multiple countries.
Symposia D
Date: Thursday, 8 May 2025
Time: 15.30 – 16.30, Afternoon
Room: Europaea
Nordic European Cutaneous Oncodermatology Management (NECOM) project tools to prevent and treat cancer therapy-related cutaneous adverse events
The Nordic European Cutaneous Oncodermatology Management (NECOM) project develops tools to prevent and treat cancer therapy-related cutaneous adverse events (cAEs). This project aims to develop evidence-based algorithms that aim to improve patient and survivor comfort during and after treatment, reduce and treat cAEs, and promote the healing of affected skin areas by using prescription medication and skincare.
The target audience is not only dermatologists and oncologists but also a broad range of HCPs, including nurses, physician assistants, GPs, and pharmacists.
The first 2 NECOM papers presented various cAEs and skincare regimens involving hygiene, moisturization, sun protection, and camouflage products for preventing and managing cAEs. The NECOM 3 practical algorithm focused on preventing and treating acute radiation dermatitis. The NECOM 4 practical algorithm addressed the prevention and management of cutaneous immunotherapy-related adverse events, improving cancer patients’ QoL and outcomes.
The NECOM 5 practical algorithm is intended to prevent and manage cutaneous targeted therapy-related adverse events (TTcAEs), improving cancer patients’ QoL and outcomes. Quality of life is highly important to cancer patients. Integrating skincare into treatment can improve the patient experience and support adherence to cancer treatment. It is important to recommend/select the right skincare products (both active ingredients and vehicle). Patients should be encouraged to adopt a proactive approach to caring for their skin before, during, and continue after cancer-targeted therapy.
Speakers:
Peter Bjerring, MD, Dr.Sci.
Ada Girnita, MD, PhD
Sampsa Kauppi, MD
Andreas Stensvold, MD, PhD